Open AccessEXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
Author(s) -
Е. В. Лубенникова,
Inna Ganshina,
А. Н. Луд,
Д. В. Комов,
И. В. Колядина,
Я. В. Вишневская,
И. К. Воротников,
Д. Л. Строяковский,
Nikita Savelov,
Владимир Семиглазов,
Alexey Manikhas,
А. В. Ошейчик,
Т. Б. Стрельникова,
К. Р. Зейналова,
Л. Г. Жукова
Publication year - 2017
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2017-14-40-45
Subject(s) - trastuzumab , medicine , tolerability , breast cancer , adjuvant , subcutaneous injection , oncology , chemotherapy , population , adverse effect , surgery , cancer , environmental health
The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in Russian population showed the favorable association between tpCR anf EFS. tpCR achiviement is associated with clinical benefit in HER2 positive breast cancer. For patients with difficult venous access who do not require intravenous chemotherapy currently, Subcutaneous trastuzumab allows to receive effective treatment without the risk of complications, which involves catheterization of a Central vein.